Pliant Therapeutics (PLRX) to Release Earnings on Monday

Pliant Therapeutics (NASDAQ:PLRX) is projected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Pliant Therapeutics to post earnings of ($0.44) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Pliant Therapeutics Stock Performance

Shares of PLRX stock opened at $1.24 on Monday. The stock has a market cap of $76.20 million, a PE ratio of -0.43 and a beta of 1.38. The business has a 50-day simple moving average of $1.23 and a 200-day simple moving average of $1.45. The company has a quick ratio of 13.93, a current ratio of 13.94 and a debt-to-equity ratio of 0.15. Pliant Therapeutics has a 52-week low of $1.09 and a 52-week high of $3.46.

Insiders Place Their Bets

In other Pliant Therapeutics news, CEO Bernard Coulie sold 89,375 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $1.28, for a total value of $114,400.00. Following the transaction, the chief executive officer owned 505,601 shares in the company, valued at approximately $647,169.28. This trade represents a 15.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pliant Therapeutics

A number of hedge funds have recently modified their holdings of the business. Rangeley Capital LLC boosted its position in Pliant Therapeutics by 20.4% during the second quarter. Rangeley Capital LLC now owns 60,220 shares of the company’s stock worth $70,000 after acquiring an additional 10,220 shares during the last quarter. Algert Global LLC raised its holdings in Pliant Therapeutics by 17.7% in the 3rd quarter. Algert Global LLC now owns 104,382 shares of the company’s stock valued at $154,000 after acquiring an additional 15,692 shares during the last quarter. Engineers Gate Manager LP lifted its stake in Pliant Therapeutics by 139.4% in the 2nd quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock worth $36,000 after purchasing an additional 18,300 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Pliant Therapeutics by 42.2% during the 1st quarter. Invesco Ltd. now owns 68,963 shares of the company’s stock worth $93,000 after purchasing an additional 20,449 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Pliant Therapeutics during the 2nd quarter worth approximately $30,000. 97.30% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PLRX has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. One equities research analyst has rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $3.92.

About Pliant Therapeutics

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).